| abstract |
The invention generally relates to compositions comprising antibodies and antigen-binding fragments thereof, such as humanized, chimeric, and human antibodies and antigen-binding fragments thereof, and fusion proteins, such antibodies and antigen-binding fragments thereof and fusion proteins. , Such antibodies and antigen-binding fragments thereof, as well as fusion proteins, specifically bind to MCT1, eg, human or non-human MCT1, and antagonize one or more MCT1-related functions in vitro and / or in vivo. Inhibits or blocks. The present invention also relates to the therapeutic and diagnostic use of these anti-MCT1 antibodies, antigen-binding fragments, fusion proteins, and the compositions containing them, optionally these anti-MCT1 antibodies, antigen-binding fragments, fusion proteins. And the compositions it contains are used in therapeutic regimens that further include administration of other therapeutic agents, such as mitochondrial inhibitors and / or biguanides or small molecule MCT1 inhibitors. [Selection diagram] Fig. 1 |